Radioimmunoimaging diagnosis of human bladder carcinoma

The monoclonal antibody (BDI-1) against human bladder carcinoma has been shown to have selective reactivity for bladder cancer. A total of 19 bladder cancer patients were studied by radioimmunoimaging (RII) and a clear immunoscintigraphy was observed in all. Blood samples collected at 1, 2, 3, days after instillation were shown to be almost free from radioactivity. It is suggested that BDI-1, as a target carrier, might also be for instillation target treatment of superficial bladder cancer.